There are no reviewed versions of this page, so it may not have been checked for adherence to standards.
Friday, January 13, 2006
Tamiflu (generic name: Oseltamivir) a common antiviral drug used in the treatment and prophylaxis of both Influenza virus A and Influenza virus B, will be marketed in a generic form in India. It is a prodrug, which is hydrolysed hepatically to the active metabolite, the free carboxylate of oseltamivir. It was developed by Gilead Sciences and is currently marketed by Hoffmann-La Roche (Roche) under the trade name Tamiflu.
Cipla received marketing approval from the drug controller-general of India and will launch a generic version of Oseltamivir, Anti-Flu, in the domestic market this month. The drug will be priced at about Rs 1,000 per strip of 10 75 mg tablets, which is less than half the current Tamiflu market price of $60. The required dosage is two tablets every day during five days.
This page is archived, and is no longer publicly editable.
Articles presented on Wikinews reflect the specific time at which they were written and published, and do not attempt to encompass events or knowledge which occur or become known after their publication.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.
Note that some listed sources or external links may no longer be available online due to age.
This page is archived, and is no longer publicly editable.
Articles presented on Wikinews reflect the specific time at which they were written and published, and do not attempt to encompass events or knowledge which occur or become known after their publication.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.
Note that some listed sources or external links may no longer be available online due to age.
